Ann: Half Yearly Report and Accounts, page-45

The only one thing I'll point out is that you won't see the gap between receipts and operating costs widen substantially whilst a medicinal cannabis company is growing rapidly. That's because the costs of maintaining the next (bigger) crop are included in the product costs in the 4C while receipts is the money that's been received from a previous (smaller) crop. That's why I like to see the fair value gain on bios. When ECS stops expanding the receipts and costs will be determined at the same level of production and there will be a huge spike in the gap between the two.